Analysts’ Views On Cellebrite DI Ltd. (CLBT)


Cellebrite DI Ltd. (NASDAQ:CLBT) finished Friday with a subtraction of -$0.14 to close at $4.36, a downside of -3.11 percent. An average of 474,740 shares of common stock have been traded in the last five days. There was a gain of $0.17 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 314,715 shares traded, while the 50-day average volume stands at 179,836.

CLBT stock has decreased by -3.54% in the last month. The company shares reached their 1-month lowest point of $3.96 on 12/28/22. With the stock rallying to its 52-week high on 02/16/22, shares of the company touched a low of $3.80 and a high of $8.31 in 52 weeks. It has reached a new high 2 times so far this year and lost -45.64% or -$3.66 in price. In spite of this, the price is down -47.52% from the 52-week high.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Valuation Metrics

Cellebrite DI Ltd. (CLBT) has a trailing price-to-earnings (P/E) ratio of 5.00. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.13, the price-to-book (PB) ratio at 13.63, and the price-to-cash flow ratio at 99.86.

Financial Health

The quick ratio of Cellebrite DI Ltd. for the three months ended June 29 was 1.30, and the current ratio was 1.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $203.69 million compared to revenue of $246.25 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Cellebrite DI Ltd.’s return on assets was 49.40%.

Earnings Surprise

In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $70.43 million in the quarter, while revenues were grew 100.0%. The analyst consensus anticipated Cellebrite DI Ltd.’s latest quarter earnings to come in at $0.03 per share, but it turned out to be $0, a -100.00% surprise. For the quarter, EBITDA amounted to $1.11 million. At the end of the quarter ending June 29, Cellebrite DI Ltd.’s stock balance sheet showed total liabilities of 293.03 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Cellebrite DI Ltd. (CLBT) price momentum. RSI 9-day as of the close on 30 December was 53.45%, suggesting the stock is Neutral, with historical volatility in this time frame at 59.98%.

As of today, CLBT’s price is $4.25 +4.06% or $0.17 from its 5-day moving average. CLBT is currently trading -7.04% lower than its 20-day SMA and -19.71% lower than its 100-day SMA. However, the stock’s current price level is -1.13% below the SMA50 and -30.79% below the SMA200.

The stochastic %K and %D were 64.99% and 45.42%, respectively, and the average true range (ATR) was 0.27. With the 14-day stochastic at 60.61% and the average true range at 0.26, the RSI (14) stands at 50.71%. The stock has reached 0.14 on the 9-day MACD Oscillator while the 14-day reading was at 0.12.

Analyst Ratings

William Blair downgraded Cellebrite DI Ltd. (NASDAQ: CLBT) to a a Mkt perform rating in its most recent analyst report. Previously, the stock was rated as an Outperform. The consensus rating for Cellebrite DI Ltd. (CLBT) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell CLBT, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 3 others rate it as a “buy”.

What is CLBT’s price target for the next 12 months?

Analysts predict a range of price targets between $6.00 and $10.00, with a median target of $7.25. Taking a look at these predictions, the average price target given by analysts for Cellebrite DI Ltd. (CLBT) stock is $7.63.


Please enter your comment!
Please enter your name here